Compare OSPN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | ALT |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.0M | 421.5M |
| IPO Year | 2000 | 2005 |
| Metric | OSPN | ALT |
|---|---|---|
| Price | $10.98 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.67 | ★ $17.67 |
| AVG Volume (30 Days) | 530.4K | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.91% | N/A |
| EPS Growth | ★ 28.77 | 25.37 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | $41,000.00 |
| Revenue This Year | $3.22 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $5.64 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $10.07 | $2.87 |
| 52 Week High | $18.13 | $7.73 |
| Indicator | OSPN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 40.69 |
| Support Level | $10.20 | $2.89 |
| Resistance Level | $10.98 | $4.25 |
| Average True Range (ATR) | 0.38 | 0.17 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 67.80 | 54.48 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.